Brazil's regulatory agency, ANVISA, is updating its rules for Software as a Medical Device (SaMD) as a key priority for 2025. This major overhaul will align Brazil’s digital health landscape with global standards like the EU MDR, introducing stricter requirements for cybersecurity, interoperability, and technical documentation. This change presents a critical challenge for MedTech innovators. For example, a US-based AI diagnostics company eager to enter the lucrative Brazilian market now faces new, complex questions. How can they ensure their existing cybersecurity protocols meet ANVISA's new, currently undefined standards? The fear of a delayed or rejected submission due to non-compliance with these evolving rules could stall their entire LATAM expansion strategy, making proactive guidance essential. Key Takeaways: 1. How will ANVISA's new SaMD framework specifically align with the EU's MDR, and what does this mean for documentation? 2. What new cybersecurity and data privacy requirements must your software meet to gain approval in Brazil? 3. Will the updated regulations create a faster or more complex path to market for digital health startups? 4. What specific changes to Instructions for Use (IFU) will be mandatory for all SaMDs? 5. How can you prepare your technical dossier now for the anticipated 2025 changes? 6. What are the new expectations for demonstrating software interoperability with existing hospital systems? 7. How will the risk classification for SaMDs change under the new Brazilian framework? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. We act as your local representative, develop efficient regulatory strategies, and use AI to compile and submit technical documents. Contact Pure Global at [email protected] or visit us at https://pureglobal.com/.